These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 25238135)

  • 1. Mixed-ligand complexes of yttrium-90 dialkyldithiocarbamates with 1,10-phenanthroline as a possible agent for therapy of hepatocellular carcinoma.
    Lopez A; Noiret N; Garin E; Lepareur N
    Appl Radiat Isot; 2014 Dec; 94():241-246. PubMed ID: 25238135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of Semiautomated Module for Preparation of
    Mukherjee A; Subramanian S; Ambade R; Avhad B; Dash A; Korde A
    Cancer Biother Radiopharm; 2017 Feb; 32(1):33-37. PubMed ID: 28128645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preparation of 177Lu-labeled oxine in lipiodol as a possible agent for therapy of hepatocellular carcinoma: a preliminary animal study.
    Subramanian S; Das T; Chakraborty S; Sarma HD; Banerjee S; Samuel G; Venkatesh M
    Cancer Biother Radiopharm; 2010 Oct; 25(5):539-43. PubMed ID: 20849309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic arterial yttrium 90 microspheres: another treatment option for hepatocellular carcinoma.
    Dawson LA
    J Vasc Interv Radiol; 2005 Feb; 16(2 Pt 1):161-4. PubMed ID: 15713916
    [No Abstract]   [Full Text] [Related]  

  • 5. Therapeutic efficacy of 188Re-MN-16ET lipiodol in an animal model of hepatocellular carcinoma.
    Huang PW; Tsai SC; Luo TY; Kao CH; Lin WY
    Ann Nucl Med; 2013 Jul; 27(6):532-7. PubMed ID: 23479326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 90Y-oxine-ethiodol, a potential radiopharmaceutical for the treatment of liver cancer.
    Yu J; Häfeli UO; Sands M; Dong Y
    Appl Radiat Isot; 2003 May; 58(5):567-73. PubMed ID: 12735973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and application of 188Re-MN-16ET/Lipiodol in a hepatocellular carcinoma animal model.
    Tang IC; Luo TY; Liu SW; Chan SH; Kung HC; Peng CL; Lin WY; Chang Y; Lin WJ
    Nucl Med Biol; 2011 Oct; 38(7):1043-52. PubMed ID: 21831647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Superselective yttrium-90 radioembolization for hepatocellular carcinoma in high-risk cases: another tool in the toolbox.
    Brown KT
    J Vasc Interv Radiol; 2014 Jul; 25(7):1073-4. PubMed ID: 24968727
    [No Abstract]   [Full Text] [Related]  

  • 9. Radioembolisation for treatment of pediatric hepatocellular carcinoma.
    Hawkins CM; Kukreja K; Geller JI; Schatzman C; Ristagno R
    Pediatr Radiol; 2013 Jul; 43(7):876-81. PubMed ID: 23212597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival after 131I-labeled lipiodol therapy for hepatocellular carcinoma. A single-center study based on a long-term follow-up.
    Ahmadzadehfar H; Habibi E; Ezziddin S; Wilhelm K; Fimmers R; Spengler U; Palmedo H; Strunk H; Schild HH; Biersack HJ; Risse J
    Nuklearmedizin; 2014; 53(2):46-53. PubMed ID: 24468919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intra-arterial injection of 131I-labeled Lipiodol for advanced hepatocellular carcinoma: a 7 years' experience.
    Lintia-Gaultier A; Perret C; Ansquer C; Eugène T; Kraeber-Bodéré F; Frampas E
    Nucl Med Commun; 2013 Jul; 34(7):674-81. PubMed ID: 23587835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radionuclide therapy for hepatocellular carcinoma.
    Lambert B; Van Vlierberghe H; Troisi R; Defreyne L
    Acta Gastroenterol Belg; 2010; 73(4):484-8. PubMed ID: 21299159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A kit formulation for the preparation of 188Re-lipiodol: preclinical studies and preliminary therapeutic evaluation in patients with unresectable hepatocellular carcinoma.
    Boschi A; Uccelli L; Duatti A; Colamussi P; Cittanti C; Filice A; Rose AH; Martindale AA; Claringbold PG; Kearney D; Galeotti R; Turner JH; Giganti M
    Nucl Med Commun; 2004 Jul; 25(7):691-9. PubMed ID: 15208496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of hepatocellular carcinoma: a pivotal role for nuclear medicine?
    Buscombe JR; Padhy A
    Nucl Med Commun; 2001 Feb; 22(2):119-20. PubMed ID: 11258396
    [No Abstract]   [Full Text] [Related]  

  • 15. Usefulness of radioembolization in identifying patients with favorable tumor biology before living donor liver transplantation.
    Yu YD; Kim DS; Jung SW; Kim Y; Suh SO
    Transplantation; 2014 Sep; 98(5):e47-50. PubMed ID: 25171535
    [No Abstract]   [Full Text] [Related]  

  • 16. Yttrium-90 microspheres (TheraSphere and SIR-Spheres) for the treatment of unresectable hepatocellular carcinoma.
    Allison C
    Issues Emerg Health Technol; 2007 Sep; (102):1-6. PubMed ID: 17824141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Automation of labelling of Lipiodol with high-activity generator-produced 188Re.
    Lepareur N; Ardisson V; Noiret N; Boucher E; Raoul JL; Clément B; Garin E
    Appl Radiat Isot; 2011 Feb; 69(2):426-30. PubMed ID: 21106381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved freeze-dried kit for the preparation of
    Mallia MB; Chirayil V; Dash A
    Appl Radiat Isot; 2018 Jul; 137():147-153. PubMed ID: 29625347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current role of selective internal radiation with yttrium-90 in liver tumors.
    Lau WY; Teoh YL; Win KM; Lee RC; de Villa VH; Kim YH; Liang PC; Santos-Ocampo RS; Lo RH; Lim KB; Tai DW; Ng DC; Irani FG; Gogna A; Chow PK
    Future Oncol; 2016 May; 12(9):1193-204. PubMed ID: 27007495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of intrahepatic I-131 ethiodol on a patient with hepatocellular carcinoma. Therapeutic feasibility study.
    Park CH; Suh JH; Yoo HS; Lee JT; Kim DI
    Clin Nucl Med; 1986 Jul; 11(7):514-7. PubMed ID: 3015472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.